
    
      This study is to compare the efficacy and the safety of topical Haposine-S and RestasisÂ® eye
      drop 0.05% for the patients with moderate to severe dry eye disease in a multicenter,
      investigator(assessor) blind, parallel design, non-inferiority phase III trial.

      Primary outcome is the change of corneal staining score(Oxford scheme) at 12 weeks from
      baseline.
    
  